Targeting truncated retinoid X receptor-α by CF31 induces TNF-α-dependent apoptosis

Cancer Research

Volumn 73, Issue 1, 2013, Pages 307-318

  Wang, Guang Hui ^a   Jiang, Fu Quan ^a   Duan, Ying Hui ^b   Zeng, Zhi Ping ^a   Chen, Fan ^a   Dai, Yi ^b   Chen, Jie Bo ^c   Liu, Jin Xing ^a   Liu, Jie ^a   Zhou, Hu ^a,c   Chen, Hai Feng ^a   Zeng, Jin Zhang ^a   Su, Ying ^c   Yao, Xin Sheng ^b   Zhang, Xiao Kun ^a,c  

^a XIAMEN UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CASPASE 8; CF31; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P85; PROTEIN P85ALPHA; RETINOID X RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SUBUNIT; GENE REPRESSION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CLUSIACEAE; HUMANS; IMMUNOPRECIPITATION; MICROSCOPY, FLUORESCENCE; MODELS, MOLECULAR; PHYTOTHERAPY; PLANT STEMS; RETINOID X RECEPTOR ALPHA; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; XANTHONES;

EID: 84871948626     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2038     Document Type: Article

References (59)

1. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93.
2. Dawson MI, Zhang XK. Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid. Curr Med Chem 2002;9:623-37.
3. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multi-functional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007;7:357-69.
4. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83:841-50.
5. Huang J, Powell WC, Khodavirdi AC, Wu J, Makita T, Cardiff RD, et al. Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. Cancer Res 2002;62:4812-9.
6. Li M, Indra AK, Warot X, Brocard J, Messaddeq N, Kato S, et al. Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature 2000;407:633-6.
7. Matsushima-Nishiwaki R, Okuno M, Adachi S, Sano T, Akita K, Moriwaki H, et al. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 2001;61:7675-82.
8. Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, et al. Synergistic effects of RXR{alpha} and PPAR gamma ligands to inhibit growth in human colon cancer cells-phosphorylated RXR{alpha} is a critical target for colon cancer management1. Gut 2007;56:1557-63.
9. Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Sasano H. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Jpn J Cancer Res 2000;91:1169-76.
10. Jiang SY, Shen SR, Shyu RY, Yu JC, Harn HJ, Yeh MY, et al. Expression of nuclear retinoid receptors in normal, premalignant and malignant gastric tissues determined by in situ hybridization. Br J Cancer 1999;80:206-14.
11. Lotan Y, Xu XC, Shalev M, Lotan R, Williams R, Wheeler TM, et al. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol 2000;18:116-21.
12. Picard E, Seguin C, Monhoven N, Rochette-Egly C, Siat J, Borrelly J, et al. Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J Natl Cancer Inst 1999;91:1059-66.
13. Takiyama Y, Miyokawa N, Sugawara A, Kato S, Ito K, Sato K, et al. Decreased expression of retinoid X receptor isoforms in human thyroid carcinomas. J Clin Endocrinol Metab 2004;89:5851-61.
14. Zhong C, Yang S, Huang J, Cohen MB, Roy-Burman P. Aberration in the expression of the retinoid receptor, RXRalpha, in prostate cancer. Cancer Biol Ther 2003;2:179-84.
15. Casas F, Daury L, Grandemange S, Busson M, Seyer P, Hatier R, et al. Endocrine regulation of mitochondrial activity:involvement of truncated RXRalpha and c-Erb Aalpha1 proteins. FASEB J 2003;17:426-36.
16. Nagaya T, Murata Y, Yamaguchi S, Nomura Y, Ohmori S, Fujieda M, et al. Intracellular proteolytic cleavage of 9-cis-retinoic acid receptor alpha by cathepsin L-type protease is a potential mechanism for modulating thyroid hormone action. J Biol Chem 1998;273:33166-73.
17. Prufer K, Schroder C, Hegyi K, Barsony J. Degradation of RXRs influences sensitivity of rat osteosarcoma cells to the antiproliferative effects of calcitriol. Mol Endocrinol 2002;16:961-76.
18. Nomura Y, Nagaya T, Yamaguchi S, Katunuma N, Seo H. Cleavage of RXRalpha by a lysosomal enzyme, cathepsin L-type protease. Biochem Biophys Res Commun 1999;254:388-94.
19. Zeisig BB, Kwok C, Zelent A, Shankaranarayanan P, Gronemeyer H, Dong S, et al. Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell 2007;12:36-51.
20. Zhu J, Nasr R, Pérès L, Riaucoux-Lormière F, Honoré N, Berthier C, et al. RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 2007;12:23-35.
21. Cao X, Liu W, Lin F, Li H, Kolluri SK, Lin B, et al. Retinoid X receptor regulates Nur77/TR3-dependent apoptosis [corrected] by modulating its nuclear export and mitochondrial targeting. Mol Cell Biol 2004;24:9705-25.
22. Ghose R, ZimmermanTL, Thevananther S, Karpen SJ. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation. Nucl Recept 2004;2:4.
23. Katagiri Y, Takeda K, Yu ZX, Ferrans VJ, Ozato K, Guroff G. Modulation of retinoid signalling through NGF-induced nuclear export of NGFI-B. Nat Cell Biol 2000;2:435-40.
24. Zimmerman TL, Thevananther S, Ghose R, Burns AR, Karpen SJ. Nuclear export of retinoid X receptor alpha in response to interleukin-1beta-mediated cell signaling: roles for JNK and SER260. J Biol Chem 2006;281:15434-40.
25. Dufour JM, Kim KH. Cellular and subcellular localization of six retinoid receptors in rat testis during postnatal development: identification of potential heterodimeric receptors. Biol Reprod 1999;61:1300-8.
26. Fukunaka K, Saito T, Wataba K, Ashihara K, Ito E, Kudo R. Changes in expression and subcellular localization of nuclear retinoic acid receptors in human endometrial epithelium during the menstrual cycle. Mol Hum Reprod 2001;7:437-46.
27. Li H, Kolluri SK, Gu J, Dawson MI, Cao X, Hobbs PD, et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000;289:1159-64.
28. Lin B, Kolluri S, Lin F, Liu W, Han YH, Cao X, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004;116:527-40.
29. Zhou H, Liu W, Su Y, Wei Z, Liu J, Kolluri SK, et al. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell 2010;17:560-73.
30. Pinto MM, Sousa ME, Nascimento MS. Xanthone derivatives: new insights in biological activities. Curr Med Chem 2005;12:2517-38.
31. Na Y. Recent cancer drug development with xanthone structures. J Pharm Pharmacol 2009;61:707-12.
32. Pedraza-Chaverri J, Cardenas-Rodriguez N, Orozco-Ibarra M, Perez-Rojas JM. Medicinal properties of mangosteen (Garcinia mangostana). Food Chem Toxicol 2008;46:3227-39.
33. Akao Y, Nakagawa Y, Iinuma M, Nozawa Y. Anti-cancer effects of xanthones from pericarps of mangosteen. Int J Mol Sci 2008;9:355-70.
34. Duan YH, Dai Y, Wang GH, Chen HF, Gao H, Chen JB, et al. Xanthone and benzophenone glycosides from the stems of Cratoxylum formosum ssp. pruniflorum. Chem Pharm Bull (Tokyo) 2011;59:231-4.
35. Duan YH, Dai Y, Wang GH, Zhang X, Chen HF, Chen JB, et al. Bioactive xanthones from the stems of Cratoxylum formosum ssp. pruniflorum. J Nat Prod 2010;73:1283-7.
36. Mahabusarakam W, Nuangnaowarat W, Taylor WC. Xanthone derivatives from Cratoxylum cochinchinense roots. Phytochemistry 2006;67:470-4.
37. Zhang XK, Lehmann J, Hoffmann B, Dawson MI, Cameron J, Graupner G, et al. Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature 1992;358:587-91.
38. Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, et al. The Amber biomolecular simulation programs. J Comput Chem 2005;26:1668-88.
39. Lu J, Dawson MI, HuQY, Xia Z, Dambacher JD, Ye M, et al. The effect of antagonists on the conformational exchange of the retinoid X receptor alpha ligand-binding domain. Magn Reson Chem 2009;47:1071-80.
40. Nahoum V, Pérez E, Germain P, Rodríguez-Barrios F, Manzo F, Kammerer S, et al. Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function. Proc Natl Acad Sci U S A 2007;104:17323-8.
41. Sato Y, Ramalanjaona N, Huet T, Potier N, Osz J, Antony P, et al. The "Phantom Effect" of the Rexinoid LG100754: structural and functional insights. PLoS ONE 2010;5:e15119.
42. Egea PF, Mitschler A, Moras D. Molecular recognition of agonist ligands by RXRs. Mol Endocrinol 2002;16:987-97.
43. Egea PF, Mitschler A, Rochel N, Ruff M, Chambon P, Moras D. Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. EMBO J 2000;19:2592-601.
44. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000;33:889-97.
45. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
46. Kolluri SK, Zhu X, Zhou X, Lin B, Chen Y, Sun K, et al. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 2008;14:285-98.
47. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71.
48. Mocellin S, Nitti D. TNF and cancer: the two sides of the coin. Front Biosci 2008;13:2774-83.
49. Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 2007;130:769-74.
50. Kupchan SM, Streelman DR, Sneden AT. Psorospermin, a new anti-leukemic xanthone from Psorospermum febrifugum. J Nat Prod 1980;43:296-301.
51. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844-50.
52. Matsumoto K, Akao Y, Kobayashi E, Ohguchi K, Ito T, Tanaka T, et al. Induction of apoptosis by xanthones from mangosteen in human leukemia cell lines. J Nat Prod 2003;66:1124-7.
53. Pattanaprateeb P, Ruangrungsi N, Cordell GA. Cytotoxic constituents from Cratoxylum arborescens . Planta Med 2005;71:181-3.
54. Zhang H, Li L, Chen L, Hu L, Jiang H, Shen X. Structure basis of bigelovin as a selectiveRXRagonist with a distinct binding mode. J Mol Biol 2011;407:13-20.
55. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-5.
56. Pincheira R, Castro AF, Ozes ON, Idumalla PS, Donner DB. Type 1 TNF receptor forms a complex with and uses Jak2 and c-Src to selectively engage signaling pathways that regulate transcription factor activity. J Immunol 2008;181:1288-98.
57. Bertazza L, Mocellin S. Tumor necrosis factor (TNF) biology and cell death. Front Biosci 2008;13:2736-43.
58. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006;11:397-408.
59. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 2008;29:1275-88.